Nasotracheal Intubation in Critically Ill. — NaTra-P  

Critical Care Clinical Trial

Official title: Nasotracheal Intubation vs. Conventional Airway Management in Critically Ill Patients.

Status Recruiting

Clinical Trial Summary

The aim of this prospective randomized trail is to compare nasotracheal versus orotracheal intubation in critically ill patients. We aim to study:

• required sedation depth

• rate of spontaneous breathing

• extend and possibility of physiotherapy

• vasopressor and sedative drug doses

Participants are randomized 1:1 to receive either nasotracheal or orotracheal intubation.

Clinical Trial Description

In the intensive care unit endotracheal intubation and consecutive mechanical ventilation are required for different surgical procedures, examinations and interventions in the ICU or due to respiratory insufficiency. Commonly, intubation is performed orotracheally by direct laryngoscopy after preoxygenation and administration of narcotics and a muscle relaxant. When using this technique sedation is often necessary for tolerance of the orotracheal tube. To avoid the adverse side effects of sedation and mechanical ventilation as for example hypotension, barotrauma, ventilator associated pneumonia, etc., intubation via a nasotracheal approach might be favorable. Retrospective data show that nasotracheal intubation is associated with fewer sedatives, vasopressors, and a higher rate of spontaneous breathing. As there is a paucity of data concerning the use of nasotracheal intubation in the intensive care setting the investigators aim to compare the use of orotracheal and nasotracheal tubes in a prospective randomized trial, using sedation depth as primary outcome measure. ;

Related Conditions & MeSH terms

• Critical Care
• Critical Illness
• Tracheal Intubation Morbidity

• NCT number: NCT05780385
• Study type: Interventional
• Source: Universitätsklinikum Hamburg-Eppendorf
• Contact: Pischtaz A Tariparast, MD
• Phone: +49 40 7410 57010
• Email: p.tariparast@uke.de
• Status: Recruiting
• Phase: N/A
• Start date: February 10, 2023
• Completion date: November 30, 2024